Symposium

Livestream: The Force Awakens—Unlocking the Potential of IL-23–targeted Therapies in the Treatment of IBD

Launch Date
05/04/2025 at 09:30 pm EST
Credit Amount
1.5
Credit Expires
05/04/2025

Faculty

Miguel Regueiro, MD
Moderator
Chief, Digestive Disease Institute
Professor in the Department of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland, OH
Miguel Regueiro, MD
Moderator

Miguel Regueiro earned his bachelor’s degree at the University of Pennsylvania, his medical degree at Drexel (Hahnemann) University and completed his internal medicine internship, residency, and clinical and research fellowship training in gastroenterology at Harvard Medical School’s Beth Israel Hospital.

Dr. Regueiro was Professor of Medicine and Clinical and Translational Science at the University of Pittsburgh School of Medicine from 2000 to 2018. There he served as the IBD Clinical Medical Director, Senior Medical Lead of Specialty Medical Homes, was Professor with Tenure, and honored as the UPMC Endowed Chair for Patient Centered Care in Inflammatory Bowel Diseases.

Dr. Regueiro is currently the Chair of the Department of Gastroenterology and Hepatology and Chair of the Digestive Disease and Surgery Institute at Cleveland Clinic in Ohio. He serves as Medical Co- Chair of Digestive Disease and Surgical Institute Research Governance committee and is Professor of Medicine at the Lerner College of Medicine, Cleveland Clinic.

Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases with a focus on the natural course of these diseases and postoperative prevention of Crohn’s disease. Recently, he has been involved in transformative medicine initiatives and developing new models of healthcare, including the first-of-its kind specialty medical home for IBD. Dr. Regueiro is investigating alternative models of care in population-based health that integrates patients, payers, providers, pharmaceutical industry, and other facets of healthcare delivery around these novel programs.

Marita Kametas, MSN, APN, FNP-BC, CMSRN, COCN
Inflammatory Bowel Disease Advanced Practice Nurse
Manager of Gastroenterology Advanced Practice Provider Services
The University of Chicago Medicine
Chicago, IL
Edward V. Loftus, Jr., MD
Maxine and Jack Zarrow Family Professor of Gastroenterology Specifically in IBD
Division of Gastroenterology and Hepatology
Mayo Clinic College of Medicine and Science
Co-Director, Advanced Inflammatory Bowel Disease Fellowship
Mayo Graduate School of Medicine
Rochester, MN
Millie D. Long, MD, MPH
Professor of Medicine 
Vice-Chief for Education
Director, Gastroenterology and Hepatology Fellowship Program
Division of Gastroenterology and Hepatology 
University of North Carolina 
Chapel Hill, NC 
Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration

Statement of Need

The therapeutic armamentarium for inflammatory bowel disease (IBD) is expanding with the advent of anti–IL-23 therapies. The unique clinical profiles of new and emerging agents make it necessary that treatment decisions are guided by evolving knowledge of the science surrounding cytokine-targeting therapies. With an established efficacy in treating both bio-naïve and bio-experienced patients, and the increased flexibility in administration routes (intravenous vs subcutaneous), the growing class of distinctive IL-23–targeting agents amplifies the importance of clinicians utilizing the most current research and guidelines when determining with patients where to best position IL-23 agents in the treatment of their IBD.

In this CME Outfitters livestream symposium, faculty will examine how pro-inflammatory cytokines drive inflammation in the pathogenesis of IBD, explore the role of the IL-23/Th17 inflammatory axis in IBD pathogenesis, and discuss the clinical implications of anti–IL-23 agents used in the treatment of IBD to bind to CD64 receptors on IL-23–producing cells.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Assess the role of pro-inflammatory cytokines in driving inflammation in the pathogenesis of inflammatory bowel disease (IBD)
  • Identify the role of the IL-23/Th17 inflammatory axis in IBD pathogenesis
  • Evaluate the clinical implications of anti–IL-23 agents used in the treatment of IBD to bind to CD64 receptors on IL-23-producing cells

Financial Support

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Target Audience

Gastroenterologists, gastroenterology fellows/trainees, physician associates (PAs), nurse practitioners (NPs), and nurses 

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 1.5

CME Outfitters, LLC, designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.5

This activity is designated for 1.50 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Physician Assistants (AAPA): 1.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr. Regueiro reports the following financial relationships:

Consultant: AbbVie Inc; Amgen Inc.; Boehringer Ingelheim; Bristol Myers Squibb Company; Celgene Corporation; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer Inc.; Prometheus Biosciences, Inc.; Salix Pharmaceuticals; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.

Ms. Kametas reports the following financial relationships:

Advisory Board: Lilly and Pfizer Inc.

Consultant: TKG Therapeutics, Inc.

Grants: GI Research Foundation

Speakers Bureau: AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Pfizer Inc.

Dr. Loftus reports the following financial relationships:

Advisory Board: Lilly and Morphic Therapeutic, Inc.

Consultant: AbbVie Inc.; Alvotech; Amgen Inc.; Arena Pharmaceuticals, Inc.; Astellas Pharma Inc.; Avalo Therapeutics, Inc.; Boehringer Ingelheim; Bristol Myers Squibb Company; Celltrion, Inc.; Fresenius Kabi; Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Gossamer Bio; Iterative Health; Janssen Pharmaceuticals, Inc.; Ono Pharma USA, Inc.; Protagonist Therapeutics Inc.; Sun. Pharma; Surrozen; Takeda Pharmaceuticals U.S.A.; TR1X Bio; and UCB, Inc.

Grants: AbbVie Inc.; AstraZeneca; Bristol Myers Squibb Company; Celgene Corporation/Receptos, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A.; Theravance Biopharma; and UCB, Inc.

Stock Shareholder (directly purchased): Exact Sciences Corporation

Dr. Long reports the following financial relationships:

Consultant: AbbVie Inc.; Bristol Myers Squibb Company; Intercept Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer Inc.; Prometheus Biosciences, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Target RWE

Research Support: Lilly; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

The following individuals have no financial relationships to disclose: 

Rebecca Vargas-Jackson, MD (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Chelsey Goins, PhD (Planning Committee)
Nichole Lainhart (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

MMS-150-050425-01

Livestream: The Force Awakens—Unlocking the Potential of IL-23–targeted Therapies in the Treatment of IBD
Event Date: 05/04/2025 at 09:30 pm EST
Register